Published in OBGYN and Reproduction Week, February 15th, 2010
"The endpoint of the combined analysis was progression-free Survival in second remission (PFS 2). characteristics were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of OBGYN and Reproduction Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.